Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease

Neuroscience

Volumn 315, Issue , 2016, Pages 162-174

  Platt, T L ^a   Beckett, T L ^a   Kohler, K ^a   Niedowicz, D M ^a   Murphy, M P ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Diabetes; Leptin; Obesity; Tau

Indexed keywords

LEPTIN; LEPTIN RECEPTOR; LEUCINE; MUTANT PROTEIN; PROLINE; TAU PROTEIN; MAPT PROTEIN, HUMAN; MAPT PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; FEMALE; HIPPOCAMPUS; HORMONE ACTION; HORMONE RESISTANCE; IN VIVO STUDY; LEPTIN RESISTANCE; MALE; MOUSE; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TAUOPATHY; ANIMAL; COGNITION; DEPENDOPARVOVIRUS; EXPERIMENTAL DIABETES MELLITUS; GENE VECTOR; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; COGNITION; DEPENDOVIRUS; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; GENETIC VECTORS; HEK293 CELLS; HIPPOCAMPUS; HUMANS; LEPTIN; MALE; MICE, TRANSGENIC; NEUROFIBRILLARY TANGLES; OBESITY; PHOSPHORYLATION; TAU PROTEINS;

EID: 84952885402     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.12.011     Document Type: Article

References (113)

1. Accardi G., Caruso C., Colonna-Romano G., Camarda C., Monastero R., Candore G. Can Alzheimer disease be a form of type 3 diabetes?. Rejuvenation Res 2012, 15:217-221.
2. Adeghate E., Schattner P., Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci 2006, 1084:1-29.
3. Anguiano M., Nowak R.J., Lansbury P.T. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 2002, 41:11338-11343.
4. Association AD Prevention and Management of Diabetes Complications 2013, American Diabetes Association, Alexandria, VA, USA.
5. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 2002, 103:26-35.
6. Baker L.D., Cross D.J., Minoshima S., Belongia D., Watson G.S., Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 2011, 68:51-57.
7. Banks A.S., Davis S.M., Bates S.H., Myers M.G. Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 2000, 275:14563-14572.
8. Bergman M. Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine 2013, 43:504-513.
9. Bjorbaek C., Buchholz R.M., Davis S.M., Bates S.H., Pierroz D.D., Gu H., Neel B.G., Myers M.G., Flier J.S. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem 2001, 276:4747-4755.
10. Burguera B., Couce M.E., Long J., Lamsam J., Laakso K., Jensen M.D., Parisi J.E., Lloyd R.V. The long form of the leptin receptor (OB-Rb) is widely expressed in the human brain. Neuroendocrinology 2000, 71:187-195.
11. Campfield L.A., Smith F.J., Guisez Y., Devos R., Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995, 269:546-549.
12. Cavallini A., Brewerton S., Bell A., Sargent S., Glover S., Hardy C., Moore R., Calley J., Ramachandran D., Poidinger M., Karran E., Davies P., Hutton M., Szekeres P., Bose S. An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease. J Biol Chem 2013, 288:23331-23347.
13. Cearley C.N., Wolfe J.H. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 2006, 13:528-537.
14. Chen R.H., Jiang X.Z., Zhao X.H., Qin Y.L., Gu Z., Gu P.L., Zhou B., Zhu Z.H., Xu L.Y., Zou Y.F. Risk factors of mild cognitive impairment in middle aged patients with type 2 diabetes: a cross-section study. Ann Endocrinol (Paris) 2012, 73:208-212.
15. Chen J., Liang L., Zhan L., Zhou Y., Zheng L., Sun X., Gong J., Sui H., Jiang R., Zhang F., Zhang L. ZiBuPiYin recipe protects db/db mice from diabetes-associated cognitive decline through improving multiple pathological changes. PLoS One 2014, 9:e91680.
16. Cheung A.K., Fung M.K., Lo A.C., Lam T.T., So K.F., Chung S.S., Chung S.K. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes 2005, 54:3119-3125.
17. Chua S.C., Chung W.K., Wu-Peng X.S., Zhang Y., Liu S.M., Tartaglia L., Leibel R.L. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996, 271:994-996.
18. Clements R.S., Robison W.G., Cohen M.P. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. J Diabetes Complications 1998, 12:28-33.
19. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., Ohannesian J.P., Marco C.C., McKee L.J., Bauer T.L., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996, 334:292-295.
20. Cota D., Proulx K., Smith K.A., Kozma S.C., Thomas G., Woods S.C., Seeley R.J. Hypothalamic mTOR signaling regulates food intake. Science 2006, 312:927-930.
21. Cota D., Matter E.K., Woods S.C., Seeley R.J. The role of hypothalamic mammalian target of rapamycin complex 1 signaling in diet-induced obesity. J Neurosci 2008, 28:7202-7208.
22. Couce M.E., Burguera B., Parisi J.E., Jensen M.D., Lloyd R.V. Localization of leptin receptor in the human brain. Neuroendocrinology 1997, 66:145-150.
23. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 2005, 26(Suppl. 1):65-69.
24. Desai G., Zheng C., Geetha T., Mathews S.T., White B.D., Huggins K.W., Zizza C.A., Broderick T.L., Babu J.R. The pancreas-brain axis: insight into disrupted mechanisms associating type 2 diabetes and Alzheimer's disease. J Alzheimers Dis 2014.
25. Dicou E., Attoub S., Gressens P. Neuroprotective effects of leptin in vivo and in vitro. NeuroReport 2001, 12:3947-3951.
26. Duque S., Joussemet B., Riviere C., Marais T., Dubreil L., Douar A.M., Fyfe J., Moullier P., Colle M.A., Barkats M. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009, 17:1187-1196.
27. Elias C.F., Aschkenasi C., Lee C., Kelly J., Ahima R.S., Bjorbaek C., Flier J.S., Saper C.B., Elmquist J.K. Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area. Neuron 1999, 23:775-786.
28. Farr S.A., Banks W.A., Morley J.E. Effects of leptin on memory processing. Peptides 2006, 27:1420-1425.
29. Ferreira S.T., Clarke J.R., Bomfim T.R., De Felice F.G. Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimers Dement 2014, 10:S76-S83.
30. Ford E.S., Williamson D.F., Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 1997, 146:214-222.
31. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001, 359:1-16.
32. Freude S., Plum L., Schnitker J., Leeser U., Udelhoven M., Krone W., Bruning J.C., Schubert M. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 2005, 54:3343-3348.
33. Furman J.L., Sama D.M., Gant J.C., Beckett T.L., Murphy M.P., Bachstetter A.D., Van Eldik L.J., Norris C.M. Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci 2012, 32:16129-16140.
34. Gotz J., Chen F., Barmettler R., Nitsch R.M. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 2001, 276:529-534.
35. Greco S.J., Sarkar S., Johnston J.M., Zhu X., Su B., Casadesus G., Ashford J.W., Smith M.A., Tezapsidis N. Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells. Biochem Biophys Res Commun 2008, 376:536-541.
36. Greco S.J., Bryan K.J., Sarkar S., Zhu X., Smith M.A., Ashford J.W., Johnston J.M., Tezapsidis N., Casadesus G. Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 2010, 19:1155-1167.
37. Guo Z., Jiang H., Xu X., Duan W., Mattson M.P. Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization. J Biol Chem 2008, 283:1754-1763.
38. Hakansson M.L., Meister B. Transcription factor STAT3 in leptin target neurons of the rat hypothalamus. Neuroendocrinology 1998, 68:420-427.
39. Halaas J.L., Gajiwala K.S., Maffei M., Cohen S.L., Chait B.T., Rabinowitz D., Lallone R.L., Burley S.K., Friedman J.M. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269:543-546.
40. Harding T.C., Dickinson P.J., Roberts B.N., Yendluri S., Gonzalez-Edick M., Lecouteur R.A., Jooss K.U. Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors. Hum Gene Ther 2006, 17:807-820.
41. Harris J.A., Koyama A., Maeda S., Ho K., Devidze N., Dubal D.B., Yu G.Q., Masliah E., Mucke L. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS One 2012, 7:e45881.
42. Harvey J., Ashford M.L. Leptin in the CNS: much more than a satiety signal. Neuropharmacology 2003, 44:845-854.
43. Harvey J. Leptin regulation of neuronal excitability and cognitive function. Curr Opin Pharmacol 2007, 7:643-647.
44. Iqbal K., Alonso Adel C., Chen S., Chohan M.O., El-Akkad E., Gong C.X., Khatoon S., Li B., Liu F., Rahman A., Tanimukai H., Grundke-Iqbal I. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005, 1739:198-210.
45. Jung H.J., Park S.S., Mok J.O., Lee T.K., Park C.S., Park S.A. Increased expression of three-repeat isoforms of tau contributes to tau pathology in a rat model of chronic type 2 diabetes. Exp Neurol 2011, 228:232-241.
46. Ke Y.D., Delerue F., Gladbach A., Gotz J., Ittner L.M. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 2009, 4:e7917.
47. Kim B., Backus C., Oh S., Hayes J.M., Feldman E.L. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 2009, 150:5294-5301.
48. Klein R.L., Lin W.L., Dickson D.W., Lewis J., Hutton M., Duff K., Meyer E.M., King M.A. Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau. Am J Pathol 2004, 164:347-353.
49. Klein R.L., Lin W.L., Dickson D.W., Lewis J., Hutton M., Duff K., Meyer E.M., King M.A. Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau. Am J Pathol 2004, 164:347-353.
50. Klein R.L., Dayton R.D., Tatom J.B., Henderson K.M., Henning P.P. AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Mol Ther 2008, 16:89-96.
51. Koch C., Augustine R.A., Steger J., Ganjam G.K., Benzler J., Pracht C., Lowe C., Schwartz M.W., Shepherd P.R., Anderson G.M., Grattan D.R., Tups A. Leptin rapidly improves glucose homeostasis in obese mice by increasing hypothalamic insulin sensitivity. J Neurosci 2010, 30:16180-16187.
52. Koike M.A., Green K.N., Blurton-Jones M., Laferla F.M. Oligemic hypoperfusion differentially affects tau and amyloid-{beta}. Am J Pathol 2010, 177:300-310.
53. Kosik K.S., Joachim C.L., Selkoe D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 1986, 83:4044-4048.
54. Kril J.J., Patel S., Harding A.J., Halliday G.M. Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol 2002, 103:370-376.
55. Lasagna-Reeves C.A., Castillo-Carranza D.L., Sengupta U., Guerrero-Munoz M.J., Kiritoshi T., Neugebauer V., Jackson G.R., Kayed R. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep 2012, 2:700.
56. Lee E.B. Obesity, leptin, and Alzheimer's disease. Ann N Y Acad Sci 2011, 1243:15-29.
57. Lesort M., Johnson G.V. Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience 2000, 99:305-316.
58. Levites Y., Jansen K., Smithson L.A., Dakin R., Holloway V.M., Das P., Golde T.E. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci 2006, 26:11923-11928.
59. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000, 25:402-405.
60. Li X.L., Aou S., Oomura Y., Hori N., Fukunaga K., Hori T. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 2002, 113:607-615.
61. Lieb W., Beiser A.S., Vasan R.S., Tan Z.S., Au R., Harris T.B., Roubenoff R., Auerbach S., DeCarli C., Wolf P.A., Seshadri S. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 2009, 302:2565-2572.
62. Lin W.L., Lewis J., Yen S.H., Hutton M., Dickson D.W. Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation. Am J Pathol 2003, 162:213-218.
63. Liu Y., Studzinski C., Beckett T., Guan H., Hersh M.A., Murphy M.P., Klein R., Hersh L.B. Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther 2009, 17:1381-1386.
64. Liu Y., Studzinski C., Beckett T., Murphy M.P., Klein R.L., Hersh L.B. Circulating neprilysin clears brain amyloid. Mol Cell Neurosci 2010, 45:101-107.
65. Maeda S., Sahara N., Saito Y., Murayama S., Ikai A., Takashima A. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res 2006, 54:197-201.
66. Martinez-Coria H., Green K.N., Billings L.M., Kitazawa M., Albrecht M., Rammes G., Parsons C.G., Gupta S., Banerjee P., LaFerla F.M. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 2010, 176:870-880.
67. Martinez-Coria H., Green K.N., Billings L.M., Kitazawa M., Albrecht M., Rammes G., Parsons C.G., Gupta S., Banerjee P., LaFerla F.M. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 2010, 176:870-880.
68. Marwarha G., Dasari B., Prasanthi J.R., Schommer J., Ghribi O. Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J Alzheimers Dis 2010, 19:1007-1019.
69. Messier C. Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging. Neurobiol Aging 2005, 26(Suppl 1):26-30.
70. Midena E., Segato T., Radin S., di Giorgio G., Meneghini F., Piermarocchi S., Belloni A.S. Studies on the retina of the diabetic db/db mouse. I. Endothelial cell-pericyte ratio. Ophthalmic Res 1989, 21:106-111.
71. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V.S., Marks J.S. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
72. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Titani K., Ihara Y. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem 1995, 270:823-829.
73. Morris H.R., Khan M.N., Janssen J.C., Brown J.M., Perez-Tur J., Baker M., Ozansoy M., Hardy J., Hutton M., Wood N.W., Lees A.J., Revesz T., Lantos P., Rossor M.N. The genetic and pathological classification of familial frontotemporal dementia. Arch Neurol 2001, 58:1813-1816.
74. Munzberg H., Huo L., Nillni E.A., Hollenberg A.N., Bjorbaek C. Role of signal transducer and activator of transcription 3 in regulation of hypothalamic proopiomelanocortin gene expression by leptin. Endocrinology 2003, 144:2121-2131.
75. Niedowicz D.M., Studzinski C.M., Weidner A.M., Platt T.L., Kingry K.N., Beckett T.L., Bruce-Keller A.J., Keller J.N., Murphy M.P. Leptin regulates amyloid beta production via the gamma-secretase complex. Biochim Biophys Acta 2013, 1832:439-444.
76. Niedowicz D.M., Reeves V.L., Platt T.L., Kohler K., Beckett T.L., Powell D.K., Lee T.L., Sexton T.R., Song E.S., Brewer L.D., Latimer C.S., Kraner S.D., Larson K.L., Ozcan S., Norris C.M., Hersh L.B., Porter N.M., Wilcock D.M., Murphy M.P. Obesity and diabetes cause cognitive dysfunction in the absence of accelerated beta-amyloid deposition in a novel murine model of mixed or vascular dementia. Acta Neuropathol Commun 2014, 2:64.
77. Niswender K.D., Morton G.J., Stearns W.H., Rhodes C.J., Myers M.G., Schwartz M.W. Intracellular signalling. Key enzyme in leptin-induced anorexia. Nature 2001, 413:794-795.
78. Oddo S., Caccamo A., Cheng D., Jouleh B., Torp R., LaFerla F.M. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. J Neurochem 2007, 102:1053-1063.
79. Oomura Y., Hori N., Shiraishi T., Fukunaga K., Takeda H., Tsuji M., Matsumiya T., Ishibashi M., Aou S., Li X.L., Kohno D., Uramura K., Sougawa H., Yada T., Wayner M.J., Sasaki K. Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. Peptides 2006, 27:2738-2749.
80. Ostlund R.E., Yang J.W., Klein S., Gingerich R. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. J Clin Endocrinol Metab 1996, 81:3909-3913.
81. Paz-Filho G.J., Babikian T., Asarnow R., Delibasi T., Esposito K., Erol H.K., Wong M.L., Licinio J. Leptin replacement improves cognitive development. PLoS One 2008, 3:e3098.
82. Perez-Gonzalez R., Antequera D., Vargas T., Spuch C., Bolos M., Carro E. Leptin induces proliferation of neuronal progenitors and neuroprotection in a mouse model of Alzheimer's disease. J Alzheimers Dis 2011, 24(Suppl 2):17-25.
83. Planel E., Tatebayashi Y., Miyasaka T., Liu L., Wang L., Herman M., Yu W.H., Luchsinger J.A., Wadzinski B., Duff K.E., Takashima A. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci 2007, 27:13635-13648.
84. Platt T.L., Reeves V.L., Murphy M.P. Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis. Biochim Biophys Acta 2013, 1832:1437-1448.
85. Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., Andreadis A., Wiederholt W.C., Raskind M., Schellenberg G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 1998, 43:815-825.
86. Prevention CoDCa Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011 2011, U.S. Department of Health and Human Services, Atlanta, GA.
87. Profenno L.A., Porsteinsson A.P., Faraone S.V. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 2010, 67:505-512.
88. Rahmouni K., Haynes W.G., Morgan D.A., Mark A.L. Intracellular mechanisms involved in leptin regulation of sympathetic outflow. Hypertension 2003, 41:763-767.
89. Rains J.L., Jain S.K. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med 2011, 50:567-575.
90. Resende R., Ferreiro E., Pereira C., Oliveira C.R. ER stress is involved in Abeta-induced GSK-3beta activation and tau phosphorylation. J Neurosci Res 2008, 86:2091-2099.
91. Resnick H.E., Valsania P., Halter J.B., Lin X. Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Community Health 2000, 54:596-602.
92. Rewers M., Zaccaro D., D'Agostino R., Haffner S., Saad M.F., Selby J.V., Bergman R., Savage P. Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004, 27:781-787.
93. Sayre L.M., Perry G., Harris P.L., Liu Y., Schubert K.A., Smith M.A. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 2000, 74:270-279.
94. Schmelzle K., Kane S., Gridley S., Lienhard G.E., White F.M. Temporal dynamics of tyrosine phosphorylation in insulin signaling. Diabetes 2006, 55:2171-2179.
95. Seshasai S.R., Kaptoge S., Thompson A., Di Angelantonio E., Gao P., Sarwar N., Whincup P.H., Mukamal K.J., Gillum R.F., Holme I., Njolstad I., Fletcher A., Nilsson P., Lewington S., Collins R., Gudnason V., Thompson S.G., Sattar N., Selvin E., Hu F.B., Danesh J. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364:829-841.
96. Shanley L.J., Irving A.J., Harvey J. Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. J Neurosci 2001, 21:RC186.
97. Shevtsova Z., Malik J.M., Michel U., Bahr M., Kugler S. Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp Physiol 2005, 90:53-59.
98. Shioda S., Funahashi H., Nakajo S., Yada T., Maruta O., Nakai Y. Immunohistochemical localization of leptin receptor in the rat brain. Neurosci Lett 1998, 243:41-44.
99. Spillantini M.G., Goedert M. Tau mutations in familial frontotemporal dementia. Brain 2000, 123(Pt 5):857-859.
100. Stewart R., Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999, 16:93-112.
101. Valerio A., Ghisi V., Dossena M., Tonello C., Giordano A., Frontini A., Ferrario M., Pizzi M., Spano P., Carruba M.O., Nisoli E. Leptin increases axonal growth cone size in developing mouse cortical neurons by convergent signals inactivating glycogen synthase kinase-3beta. J Biol Chem 2006, 281:12950-12958.
102. van Eersel J., Ke Y.D., Liu X., Delerue F., Kril J.J., Gotz J., Ittner L.M. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc Natl Acad Sci U S A 2010, 107:13888-13893.
103. Virkamaki A., Ueki K., Kahn C.R. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999, 103:931-943.
104. Wayner M.J., Armstrong D.L., Phelix C.F., Oomura Y. Orexin-A (Hypocretin-1) and leptin enhance LTP in the dentate gyrus of rats in vivo. Peptides 2004, 25:991-996.
105. Weingarten M.D., Lockwood A.H., Hwo S.Y., Kirschner M.W. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 1975, 72:1858-1862.
106. Williams D.R. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Intern Med J 2006, 36:652-660.
107. Winocur G., Greenwood C.E., Piroli G.G., Grillo C.A., Reznikov L.R., Reagan L.P., McEwen B.S. Memory impairment in obese Zucker rats: an investigation of cognitive function in an animal model of insulin resistance and obesity. Behav Neurosci 2005, 119:1389-1395.
108. Wood J.G., Mirra S.S., Pollock N.J., Binder L.I. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc Natl Acad Sci U S A 1986, 83:4040-4043.
109. Xu W., Qiu C., Gatz M., Pedersen N.L., Johansson B., Fratiglioni L. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 2009, 58:71-77.
110. Yaffe K., Blackwell T., Kanaya A.M., Davidowitz N., Barrett-Connor E., Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004, 63:658-663.
111. Zhang F., Wang S., Signore A.P., Chen J. Neuroprotective effects of leptin against ischemic injury induced by oxygen-glucose deprivation and transient cerebral ischemia. Stroke 2007, 38:2329-2336.
112. Zhao A.Z., Huan J.N., Gupta S., Pal R., Sahu A. A phosphatidylinositol 3-kinase phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on feeding. Nat Neurosci 2002, 5:727-728.
113. Zincarelli C., Soltys S., Rengo G., Rabinowitz J.E. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008, 16:1073-1080.